4//SEC Filing
Poulton Stuart 4
Accession 0001193125-25-205046
CIK 0001503802other
Filed
Sep 15, 8:00 PM ET
Accepted
Sep 16, 4:33 PM ET
Size
6.8 KB
Accession
0001193125-25-205046
Insider Transaction Report
Form 4
Poulton Stuart
EVP, Chief Development Officer
Transactions
- Award
Common Stock
2025-09-12+888→ 28,111 total - Sale
Common Stock
2025-09-15$6.43/sh−401$2,578→ 27,710 total
Footnotes (2)
- [F1]Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2023 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 SENTRY trial, as certified by the issuer's Compensation Committee on September 12, 2025. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on September 12, 2025.
- [F2]This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.
Documents
Issuer
Karyopharm Therapeutics Inc.
CIK 0001503802
Entity typeother
Related Parties
1- filerCIK 0001942597
Filing Metadata
- Form type
- 4
- Filed
- Sep 15, 8:00 PM ET
- Accepted
- Sep 16, 4:33 PM ET
- Size
- 6.8 KB